Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832119 | 1.00 | POLB (0.38) | POLBTDP1APLNRAPEX1CTDSP1 | |
| SCHEMBL1005287 | 1.00 | POLB (0.38) | POLBTDP1APLNRAPEX1CTDSP1 | |
| SCHEMBL14074016 | 1.00 | POLB (0.38) | POLBTDP1APLNRAPEX1CTDSP1 | |
| SCHEMBL12342891 | 0.89 | APLNR (0.35) | POLBTDP1APLNRAPEX1 | |
| SCHEMBL11950520 | 0.88 | APLNR (0.30) | POLBTDP1APLNRAPEX1 | |
| SCHEMBL1791944 | 0.86 | POLB (0.33) | POLBTDP1APLNRAPEX1CTDSP1 | |
| SCHEMBL11108301 | 0.85 | PPM1B (0.36) | POLBAPLNR | |
| SCHEMBL6175009 | 0.85 | PPM1B (0.36) | POLBTDP1APLNRAPEX1 | |
| SCHEMBL5832895 | 0.82 | POLB (0.44) | POLBTDP1APEX1CTDSP1 | |
| SCHEMBL11407715 | 0.77 | POLB (0.34) | POLBTDP1APLNRAPEX1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428099-B2 | Pharmaceutical co-crystal composition and use thereof | Syn-Nat Products Enterprise LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180186822-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF | Syn-Nat Products Enterprise LLC | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428099-B2 | Pharmaceutical co-crystal composition and use thereof | CXCR3, CCR5, CCR3 | POLB 1158/4885TDP1 1807/4885APLNR 3636/4885 |
| US-20180186822-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF | CXCR3, CCR3, CCR5 | POLB 1103/4885TDP1 1764/4885APLNR 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.